ACH-QUETIAPINE FUMARATE XR TABLET (EXTENDED-RELEASE)

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

QUETIAPINE (QUETIAPINE FUMARATE)

Inapatikana kutoka:

ACCORD HEALTHCARE INC

ATC kanuni:

N05AH04

INN (Jina la Kimataifa):

QUETIAPINE

Kipimo:

200MG

Dawa fomu:

TABLET (EXTENDED-RELEASE)

Tungo:

QUETIAPINE (QUETIAPINE FUMARATE) 200MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

60/100/1000

Dawa ya aina:

Prescription

Eneo la matibabu:

ATYPICAL ANTIPSYCHOTICS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0131858003; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2016-03-29

Tabia za bidhaa

_ACH-Quetiapine Fumarate XR (Quetiapine Fumarate Extended-Release
Tablets) _
_Page 1 of 85 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACH-QUETIAPINE FUMARATE XR
Quetiapine Fumarate Extended-Release Tablets
Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg
quetiapine
(as quetiapine fumarate), Oral Use
House Standard
Antipsychotic / Antidepressant Agent
Accord Healthcare Inc.
Date of Initial Authorization:
3535 boul. St. Charles, Suite 704
March 29, 2016
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
February 9, 2022
Submission Control No: 255984
_ACH-Quetiapine Fumarate XR (Quetiapine Fumarate Extended-Release
Tablets) _
_Page 2 of 85 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Musculoskeletal - Rhabdomyolysis
02/2022
7 WARNINGS AND PRECAUTIONS, Psychiatric
02/2022
7 WARNINGS AND PRECAUTIONS, Skin
02/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 5
4
DOSAGE AND ADMINISTRATION
............................................................